Description: NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company's trademarks include NeoFISH, NeoFlow, NeoSITE, NeoArray, NeoType, and MelanoSITE. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Home Page: www.neogenomics.com
NEO Technical Analysis
9490 NeoGenomics Way
Fort Myers,
FL
33912
United States
Phone:
239 768 0600
Officers
| Name | Title |
|---|---|
| Mr. George A. Cardoza | Pres & COO of Lab Operations |
| Ms. Kathryn B. McKenzie | Interim Chief Culture Officer, Chief Sustainability & Risk Officer |
| Mr. Christopher Michael Smith BSc | CEO & Director |
| Mr. Jeffrey S. Sherman M.B.A. | Chief Financial Officer |
| Ms. Cynthia J. Dieter | Chief Accounting Officer |
| Mr. John Mooney | Chief Technology Officer |
| Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D. | Pres of Lab Operations & Chief Scientific Officer |
| Charlie Eidson | Director of Investor Relations and Corp. Devel. |
| Mr. Hutan Hashemi J.D. | Chief Compliance Officer |
| Ms. Ali Olivio | Gen. Counsel & Corp. Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 222.2222 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3877 |
| Price-to-Sales TTM: | 2.7561 |
| IPO Date: | 1999-11-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 2000 |